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The effect of24-hours continuous somatostatin 14 infusion on the volume ofthe bile secretion and on the
bile composition were studied in seven patients with malignant biliary obstruction who had transhepatic
external biliary drainage.
The bile acid composition was measured with high performance liquid chromatography (HPLC).
Somatostatin infusion significantly reduced the daily bile loss from median 473 ml to 140 ml (41 per cent,
p 0.01) with a concomitant significant reduction in the daily molar loss ofcholesterol, triglyceride, Na/,
K/, CI-, Ca and Mg//. The loss of chloride and sodium was reduced with median 50 mmol/day each
(p 0.01). The relative concentrations of the measured bile constituents did not change significantly,
except for bile acids (p 0.02): the concentration of glycochenodeoxycholic acid increased significantly
(p 0.04). The molar loss of taurocholic acid decreased significantly (p 0.035), so the increased
concentration of glycochenodeoxycholic acid resulted only in a marginally significant reduction in the
total molar loss of bile acids (p 0.051).
Somatostatin is a potent inhibitor of bile secretion. The peptide may be used in severely bile depleted
patients for reducing their serious electrolyte and acidity problems. Analysis of bile acid composition by
HPLC is well suited for further investigations of the regulatory mechanisms of bile acid secretion.
KEY WORDS: Bile acid composition bile secretion chloride cholesterol potassium
sodium somatostatin triglyceride external biliary drainage
INTRODUCTION
Somatostatin is an ubiquitous peptide distributed in
the central, peripheral and autonomous nervous sys-
tem, in the D-cells of the gastrointestinal tract, in the
pancreas, and in other peripheral organs 1-4. It is pos-
sible that the peptide exerts its function in several
ways: as a paracrine secretion, as a true hormone, and
as a neurotransmitter 1-4.Somatostatin and its ana-
logues havemany different effects, most ofthem inhib-
iting the secretion of hormones and of several
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gastrointestinal peptides (gastrin, VIP, pancreatic
polypeptide, secretin, motilin, insulin, glucagon,
growth hormone and thyreotropine) 1’3’4. Animal ex-
periments and occasional studies in humans have
shown that somatostatin reduces bile secretion after a
short infusion time 1’4-7. In man the primary mode of
action is on the bile acid-dependent canalicular bile
flow, and to some extent on the ductular secretion 2,8.
The effect of somatostatin infusion on bile acids has
only been measured after a short infusion period, and
no studies have yet reported the specific response on
bile acid composition as measured with High Perform-
ance Liquid Chromatography (HPLC) 9,10.
The aim of the present study was to evaluate the 24
hour effect ofcontinuous somatostatin-14 infusion on
bile secretion, and on bile composition including the
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concentration ofbile acid constituents in patients with
external biliary drainage.
MATERIALS AND METHODS
Seven patients (five women and two men) with total
occlusion of the common bile duct due to non
resectable periampullary pancreatic cancer were
palliatively treated for severe symptomatic jaundice
with external biliary drainage. Catherisation of the
common bile duct was performed as a part of the
diagnostic percutaneous transhepatic cholangiography
as described by Burcharth and Nielbo 11. The volume
was diethylaminohydroxypropyl Sephadex LH-20
(lipidex DEAP) from Pachard Instruments, The Neth-
erlands, and Bond Elut C18 from Analytical Interna-
tional, USA. Solvents were of Lichrosolv Grade.
Taurine conjugated bile acid was purified by a method
used by Tangermann et al.
13 with the following modifi-
cations: after isolation of the taurine conjugated bile
acids, these were hydrolysed and the free bile acids
converted into fluorescent compounds according to
Kamada et al. 12. This separation makes it possible to
measure the different fractions of bile acids.
Biliary sodium and potassium concentrations were
determined by flame photometry; biliary chloride by
titration, and magnesium and calcium by means of
ofthe external bile secretion was measured for 24 hour atomic absorption photometry. The biliary choles-
periods during 5-9 days before the day of the investi-
gation at which time the amount of bile secreted per
day had become constant. All patients were studied
after informed consent and approval by the local Eth-
ics Commitee, and the study was conducted in accord-
ance with Helsinki Declaration II.
The patients were on oral nutrition. The median age
was 73 years (range 52-77 years) and the median
weight was 56 kg (range 33.4-72.5 kg). Each day of
investigation started at 8 am. Somatostatin-14
(DuraScan, Odense, Denmark) was given as a
continous 24 hour intravenous infusion (250 tg/hour)
by means of a perfusion pump. The infusion rate
corresponded to a dosage of 3.5-7.1 tg/h per kg body
weight (median 4.5 tg/h per kg BW). The bile was
sampled during the last hour before the start of infu-
sion and after the first, second and the last hour of
infusion. The total amount of bile secreted during the
24 hour infusion period was measured. Bile samples
were taken in dry tubes and frozen to- 20C until
analysis. The bile was analysed for concentrations of
cholesterol, triglyceride, Na+, K+, CI-, Ca++, Mg++ and
bile acids. The blood glucose level was measured four
times during the 24 hour infusion period.
Assays
Bile acids were assayed using a HPLC unit (model
Hitachi-Merck) equipped with fluorescent detection
and Lichrocart 250-4 (Merck-cat. 16056) column. The
isolation and determination of free and glycine conju-
gated bile acids in the bile was performed as described
by Kamada et al. 12. We used free and conjugated bile
acids from Steraloids Inc., USA, dicyclohexyl-18-
crown-6-ether from Merck, 1-bromacetylpyrene from
Wako Chemicals Gmbh, Germany, and cholylglycine
hydrolase from SIGMA, USA. The anion exchanger
terol and triglycerides were analysed with monotests
and peridochrom, respectively (BOERINGER
Mannheim, Germany).
STATISTICAL METHODS
Friedman test was used for comparison ofthe bile acid
constituents before and during infusion. When
Friedman test showed significant values, we used Stu-
dent-Newman-Keuls method for pairwise multiple
comparisons of significant differences (SigmaStat 1.0
Jandel Scientifics GmbH, Erkrath, Germany). All re-
suits are given as median values. The level of statistical
significance was set at p < 0.05 (two-sided).
RESULTS
Somatostatin infusion reduced the daily bile loss in all
seven patients from a median of 473 ml to 140 ml
(p 0.01, Figure 1). The median relative reduction in
the daily loss ofbile was 41% (p 0.01). The reduction
in bile secretion was seen from thefirst hour ofinfusion
and the effect seemed to increase during the infusion
period to about one third of the initial volume in the
twentyfourth hour of infusion (Table 1). The reduc-
tion in bile secretion was uncorrelated with the dosage
infused per kg body weight (Figure 1).
There were no significant changes in the concentra-
tions of the measured bile electrolytes but as the se-
creted bile volume was markedly reduced, hence the
daily loss of electrolytes was significantly reduced,
too. The most important effect concerned the loss of
sodium and chloride, as both were reduced with more
than 2 mmol/h corresponding to amedian reduction in
the daily loss of about 50 mmol (Table 1). There wasSOMATOSTATIN AND BILE SECRETION 231
Table 1 Median hourly molar loss of bile constituents before (-1 to 0), and during
somatostatin infusion. The p-values are results of Friedman test.
constituents period (hours)
-1 to 0 0 to 1 1 to 2 23 to 24 p
Cholesterol (tmol/h) 20.40 14.14 11.18 15.10 0.003
Triglycerid (tmol/h) 10.46 8.54 6.96 7.90 0.041
Na (mmol/h) 2.91 1.97 1.60 0.99 0.011
C1- (mmol/h) 2.69 1.52 1.34 0.73 0.005
K (mol/h) 103.5 57.00 45.60 35.10 0.017
Ca (tmol/h) 32.29 17.10 15.45 9.25 0.006
Mg (mol/h) 13.64 8.10 7.80 3.71 0.035
Bile volume (ml/h) 20.50 14.00 12.00 6.50 0.007
Bile volume per 24 hour (ml)
1000 q
800
600
400
200
0
7.1 3.5 7.5 6.8 4.1 4.5 4.4
Somatostatin dose (pg/h per kg body weight)
Figure 1 The diurnal bile secretion before (black columns) and during somatostatin infusion (grey columns) in seven patients arranged
in ascending order with the largest relative reduction to the right. The numbers on the abscisse under each patient shows the dosage of
somatostatin infused per hour per kg body weight.
also a significant reduction in the molar loss ofcholes-
terol and triglycerid (Table 1).
The significant increase in the concentration of
bile acids was mainly due to an increase of glycocheno-
deoxycholic acid (p=0.04) giving a significant
increase in the glycine conjugated acids (p 0.01,
Table 2). The total hourly molar loss of bile
acids showed a marginally significant reduction
(p=0.051, Table 3). The molar loss of tauro-
cholic acids decreased significantly (p=0.035)
giving a significantly decreased loss in taurine
conjugated acids (p 0.035). Also the molar loss
of chenodeoxycholic acids decreased significantly
(p 0.046). The marginally significant reduction in
total molar bile loss can be explained by a corres-
ponding increased concentration of glycochen-
odeoxycholic acids. The ratio between the cholic
acids and the chenodeoxycholic acids did not change
(p 0.89).
The levels ofsignificant differences, revealed by mul-
tiple comparison, were all found between the value
before start of infusion and one or several values
during infusion.
Serum bilirubin levels were unchanged during
the investigation and no side effects due to
somatostatin were experienced. Blood glucose re-
mained within the normal range during the 24 hours
of infusion.232 H.B. ANDERSEN et al.
Table 2 The median molar concentrations of bile acids before (-1 to 0), and during
somatostatin infusion. The p-values are results of Friedman test.
constituents period (hours)
-l to O O to l l to 2 23 to 24 p
Glycocholic acid (mmol/1) 1.25 0.70 0.90 2.00 0.08
Glycochenodeoxycholic
acids (mmol/1) 0.60 0.60 0.70 1.00 0.04
Taurocholic acid (mmol/1) 1.25 0.75 0.80 1.10 0.22
Taurochenodeoxycholic
acids (mmol/l) 2.50 2.05 2.50 2.90 0.51
Glycine conjugated acids (mmol/1) 2.60 1.65 1.90 5.00 0.01
Taurine conjugated acids (mmol/1) 4.00 3.20 3.30 5.70 0.23
Cholic acids (mmol/1) 2.50 1.40 1.40 3.10 0.10
Chenodeoxycholic acids (mmol/1) 3.30 2.50 3.00 5.10 0.19
Median of sum of bile
acids (mmol/1) 6.60 5.50 5.20 8.50 0.02
Table 3 Median hourlymolar loss ofbile acids before (-1 to 0), and during somatostatin
infusion. The p-values are results of Friedman test.
constituents period (hours)
-1 to 0 0 to 1 1 to 2 23 to 24 p
Glycocholic acid (lamol/h) 25.63 12.00
Glycochenodeoxycholic
acids (I.tmol/h) 13.60 9.00
Taurocholic acid (l.tmol/h) 25.63 12.00
Taurochenodeoxycholic
acids (ktmol/h) 60.00 23.58
Glycine conjugated acids (lamol/h) 45.10 19.60
Taurine conjugated acids (mol/h) 97.38 48.00
Cholic acids (l.tmol/h) 51.25 24.00
Chenodeoxycholic acids (tmol/h) 78.00 30.00
Median of sum of bile
acids" (l.tmol/h) 142.48 77.00
7.50 26.00 0.53
6.50 5.85 0.37
12.50 14.30 0.035
32.50 26.00 0.08
12.00 32.50 0.44
42.90 40.30 0.035
20.00 40.30 0.18
39.00 37.70 0.046
54.60 79.30 0.051
*Only one patient had small measurable amounts of free acids. These amounts are
included in his sum of bile acids.
DISCUSSION
Our study demonstrated that the reduction of bile
secretion persisted during 24 hour of somatostatin
infusion with increasing effect during the infusion
time. The present results of the somatostatin effect on
bile is in accordance with other studies but in no
studies was somatostatin infused for more than three
hours 2,8-10. In dogs, the infused dose needed to be
higher than 0.1 gg/h/kg BW to induce a reduction in
bile volume7. Doses of8-12 tg/h/kgBW decreased bile
flow, while concentrations ofcholesterol and bile acids
were unchanged 6,7. Bickerstaffand colleagues infused
48 gg/h/kg BW somatostatin for 20 minutes in dogs
and found a decrease in bile flow in accordance with
other studies 14. They recorded slightly increased con-
centrations of bile acids without definite changes in
bile acid output despite the high doses infused 14. In
rats, a dose of 20 tg/h/kg BW caused an immediate
decrease in bile flow and in bile acid output to
30-47%5, while infusion of 500 tg/h/kg BW only re-
duced the bile output by 20 % 15. Schirmer et al.
demonstrated that somatostatin had no effect on iso-
lated perfused rat liver supporting the theory that the
effect ofsomatostatin on the liver is primary indirect 15.
We used a median dose of 4.5 tg/h/kg BW which is
the manufacturer’s recommended dosage. However,
full effect can be obtained at lower dosages as illustrated
by the patient with the lowest dosage of3.5 tg/h/kgBW
who had the second largest relative reduction in bileflow
of43 % from 130 ml/24h to 56 ml/24h (Figure 1).
Somatostatin used in the present dosage seems to
influence both the bile acid dependent and the bile acid
independent canalicular flow as only the concentra-
tion ofglycocholic acid increased while that oftaurine
conjugated acids was unchanged.SOMATOSTATIN AND BILE SECRETION 233
However, the present results can not exclude that
somatostatin also influences the ductular secretion.
Further investigations are needed to reveal the exact
regulatory mechanisms of bile acid secretion.
In patients with inoperable malignant biliary ob-
struction internal biliary drainage by insertion of an
endoprosthesis may be used as a palliative treatment,
but in some patients only external biliary drainage can
be performed. It is well known that enhanced
choleresis occurs after relief ofbiliary obstruction and
in some patients with external biliary drainage the
volume and daily loss of bile constituents remain at
quite high levels resulting in a daily need for correction
of electrolytes and fluids.
Continous somatostatin infusion will probably
not become the treatment of choice in all patients
with external bile drainage. However, this treatment
may be used for the few bile depleted patients
who have a devastating daily bile loss resulting
in a disordered electrolyte and acidity status requiring
daily corrections. Somatostatin infusion may also be
used for the first few days after insertion of a
percutaneous transhepatic biliary tube or after
insertion of an endoprothesis, as the decrease in
bile secretion may assist in preventing bile leakage.
The analysis of changes in bile acid constituents by
the HPLC method appears suitable for further
investigations of the regulatory mechanisms of
bile acid secretion.
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